Ruben Olivares, MD, discusses the evolving role for focal radiation therapy in the management of prostate cancer.
Adrienne G. Waks, MD, discusses treatment alternatives in the third line and beyond for patients with metastatic HER2-positive breast cancer.
An expert panel provides their final thoughts about the future of the chronic lymphocytic leukemia (CLL) treatment landscape.
William B. Pearse, MD, discusses the current treatment paradigm for patients with relapsed/refractory mantle cell lymphoma.
Nuhad K. Ibrahim, MD, discusses the investigation of eftilagimod alpha plus in hormone receptor–positive HER2-negative or HER2-low metastatic breast cancer in the phase 3 AIPAC-003 trial.
Margaret E. Gatti-Mays, MD, MPH, FACP, discusses the current use of neoadjuvant chemoimmunotherapy in early-stage triple-negative breast cancer.
Experts in cancer care review the phase 3 AENEAS trial with aumolertinib and the cost-effectiveness.
Closing out their discussion on the management of biliary tract cancers, experts share excitement for future evolutions in the treatment landscape.
Alexandra Sokolova, MD, discusses the importance of genetic testing in patients with prostate cancer, which patients may benefit most from genetic testing, and how cascade testing can identify additional people who are at risk for developing cancer.
Elise Nassif, MD, discusses examining gut microbial signatures in the tumor microenvironment.
The addition of darolutamide to androgen deprivation therapy and docetaxel prolonged overall survival in patients with metastatic hormone-sensitive prostate cancer, irrespective of disease volume or disease risk.
Ilyas Sahin, MD, discusses the Northstar Response assay and the future of precision oncology in patients with advanced gastrointestinal cancer.
Helen Heng-Shan Moon, MD, discusses the future of care in prostate cancer.
Most hematology/oncology fellows will care for patients with venous thromboembolism throughout their training and long after their graduation from fellowship. Here are some practical considerations when treating a patient with an acute VTE.
Michael B. Atkins, MD, discusses the rationale for launching the phase 2 HCRN GU16-260 trial in patients with advanced renal cell carcinoma.
Judging from the drug pipeline, the future of oncology is oral chemotherapy.
Allison A. DiPasquale, MD, discusses the continued evaluation of Cerianna positron emission tomography scans in patients with breast cancer and highlights the need for a multidisciplinary approach when treating patients in this population.
Ricardo Costa, MD, MSC, discusses the implications of the phase 3 KEYNOTE-522 trial trial in patients with high-risk, early-stage triple-negative breast cancer.
Experts discuss the optimal monitoring of patients to identify interstitial lung disease early and how to intervene.
Expert insight to how the field of hepatocellular carcinoma management may evolve in coming years given therapeutic combinations and ongoing clinical trials.
Cheryl Saenz, MD, discusses the need for ongoing research efforts in cervical cancer.
Huma Q. Rana, MD, MPH, discusses the use of age at diagnosis to guide the utility of genetic testing in men with prostate cancer.
A closer look at some of the approaches being used across The US Oncology Network to improve patient access can provide helpful insight into how practices can meet the growing need for their services.
Hannah Walker-Mimms, MS, discusses a study revealing that Ewing and clear cell sarcomas have increased sensitivity to filanesib over other cancer types.
Gautam Borthakur, MD, discusses the ongoing phase 3 SELECT MDS-1 trial in patients with newly diagnosed myelodysplastic syndromes.
Chimeric antigen receptor T-cell therapy has proven to be an effective adoptive cellular therapy against relapsed/refractory B-cell lymphoma.
When assessing monoclonal gammopathy it is important to rule out clinically significant associations requiring treatment.
University of Wisconsin Carbone Cancer Center will be designated as a Specialized Program of Research Excellence, or SPORE, by the National Cancer Institute for research initiatives to advance new prostate cancer treatments.
Nasser Khaled Altorki, MD, discusses the results of post-hoc analyses of the phase 3 IMpower010 trial in non–small cell lung cancer.
Closing out their discussion on biliary tract cancers, Milind Javle, MD, and Laura Goff, MD, highlight current treatment guidelines and unmet needs as the landscape continues to evolve.